Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03187106 · ClinicalTrials.gov registry record · Phase 1
Prophylactic Antibiotics After Cesarean
A Phase 1 study, sponsored by The University of Texas Medical Branch, Galveston.
- Completed
- Registry status
- Phase 1
- Development phase
- 321
- Enrollment target
NCT03187106: Completed Phase 1 study, sponsored by The University of Texas Medical Branch, Galveston.
NCT03187106 is a Phase 1 study that has completed, run by The University of Texas Medical Branch, Galveston. The registered enrollment target is 321 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (435% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03187106, a Phase 1 study, has completed, sponsored by The University of Texas Medical Branch, Galveston.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 321 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the addition of a 48-hour course of post-operative antibiotics to the recommended course of pre-operative antibiotics improves surgical site infection rate in patients who are obese and undergo Cesarean section after laboring.
Primary Outcome
Including superficial or deep incisional surgical site infection, endometritis, and other related infections, such as septic pelvic thrombophlebitis and abdominal or pelvic abscess
Interventions
- DRUG Placebo
- DRUG Metronidazole
- DRUG Cephalexin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 321 participants |
| Start Date | 2017-08-01 |
| Est. Completion | 2023-07-21 |
| Phase | Phase 1 |
What the finished NCT03187106 record still lists
NCT03187106 is an interventional study that assigns participants to a tested intervention. The registered 321 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (435% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03187106 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03187106 about?
NCT03187106 is a clinical study titled "Prophylactic Antibiotics After Cesarean". The purpose of this study is to determine if the addition of a 48-hour course of post-operative antibiotics to the recommended course of pre-operative antibiotics improves surgical site infection rate in patients who are obese and undergo Cesarean section after laboring.
What is the current status of trial NCT03187106?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 321 participants. The study started on 2017-08-01. Estimated completion is 2023-07-21.
What interventions are being tested in trial NCT03187106?
The interventions under investigation include: Placebo (DRUG), Metronidazole (DRUG), Cephalexin (DRUG).
Who is sponsoring clinical trial NCT03187106?
This trial is sponsored by The University of Texas Medical Branch, Galveston, which has 203 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03187106's enrollment target sits among peer trials
321 111th of 2000 higher than 1,889 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03715933 · 321 participants · Phase 1
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- NCT05922878 · 321 participants · Phase 2
Study of ALTO-300 in MDD
- NCT04090359 · 322 participants · Phase 4
Dual Mobility Acetabular Cups in Revision TJA
- NCT04924075 · 322 participants · Phase 2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI